Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

BACKGROUND: It is important to establish the cardiovascular (CV) safety profile of novel antidiabetic drugs. METHODS: Pooled analyses were performed of 20 randomized controlled studies (N = 9156) of saxagliptin as monotherapy or add-on therapy in patients with type 2 diabetes mellitus (T2DM) as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Nayyar, Parker, Artist, Frederich, Robert, Donovan, Mark, Hirshberg, Boaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918110/
https://www.ncbi.nlm.nih.gov/pubmed/24490835
http://dx.doi.org/10.1186/1475-2840-13-33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918110/
https://www.ncbi.nlm.nih.gov/pubmed/24490835
http://dx.doi.org/10.1186/1475-2840-13-33

Ejemplares similares